5-Amino-1MQ

What is 5-Amino-1MQ, and why is it not a peptide?

5-Amino-1MQ is the abbreviation of “5-amino-1-methylquinolinium.” In 2018, a team at the University of Texas Medical Branch in Galveston, USA, compared a series of small molecules that inhibit the enzyme nicotinamide N-methyltransferase (NNMT); these compounds with a methylquinolinium scaffold crossed cell membranes easily and did not inhibit similar methyl-transferring enzymes or enzymes in the NAD+ salvage pathway. One of the most potent of them, 5-amino-1MQ, was taken into a mouse experiment. ^[1]

Peptides are chains formed by linking amino acids together. 5-Amino-1MQ, by contrast, is a small molecule built on a quinoline ring and contains no amino acid chain; in the FDA’s 2026 warning letter, the substance is also referred to as “5-amino-1-methylquinolinium iodide,” that is, as a salt. ^[8] Being sold online next to “research peptide” products does not make it a peptide; that classification belongs to marketing. What peptides are is covered in a separate guide: What are peptides?

What does the NNMT enzyme do?

NNMT adds a methyl group to nicotinamide, a form of vitamin B3. In this reaction the methyl donor S-adenosylmethionine (SAM) is consumed, and nicotinamide is excreted as 1-methylnicotinamide instead of returning to the production of NAD+, which has a role in cellular energy metabolism. A mouse study published in Nature in 2014 showed that NNMT is elevated in the fat tissue and liver of obese and diabetic mice; silencing the enzyme at the gene level in these tissues (with an antisense oligonucleotide) protected mice from diet-induced obesity and increased energy expenditure. ^[2]

5-Amino-1MQ is a test of this idea with a drug-like molecule. In cell culture, NNMT inhibitors lowered 1-methylnicotinamide levels, raised intracellular NAD+ and SAM levels, and reduced fat synthesis in fat cells. ^[1] All of these findings were obtained in a culture dish or in mice; no change in NAD+ or SAM measured with 5-amino-1MQ in human tissue has been published.

What do the mouse studies show?

The table below lists the published animal studies conducted with 5-amino-1MQ, with their model and limitation. All were done in mice.

Read together, the two studies show that 5-amino-1MQ could limit weight gain and shrink fat tissue in obese mice. However, the effect was dose-dependent: in the 2024 study, the low-dose group did not differ from the control group in weight. ^[5] Weight percentages in mouse models cannot be translated into weight loss in humans; whether a substance works in humans can only be shown by a human study.

Do oral capsules work?

This question has not been answered in humans. In the 2024 study, the absolute bioavailability of orally given 5-amino-1MQ in mice was about 3.5%. Although the substance dissolves very well in water, it was absorbed only to a limited extent from the gut; the authors explained the low rate by limited absorption and high first-pass breakdown in the liver. With subcutaneous administration, distribution to fat, muscle, and liver tissue was shown. ^[5] This means that only a very small fraction of an oral dose in mice reaches the blood; absorption in humans has not been measured.

Aged muscle and exercise claims

The marketing of 5-amino-1MQ as “muscle-protective” rests on two studies in aged mice.

• Repair after muscle injury (2019): Chemical injury was induced in the leg muscle of 24-month-old mice, and the animals were treated for 1 or 3 weeks. In treated mice, proliferation of muscle stem cells increased, the cross-sectional area of repaired muscle fibers grew about 2-fold, and the peak contractile force of the injured muscle was about 70% higher than in controls. ^[3]
• Combined with exercise (2024): 35 female mice aged 22 months were divided into four groups over 8 weeks. Grip strength was about 40% higher in the sedentary treated group than in sedentary controls, about 20% higher in the exercise-only group, and about 60% higher in the group receiving treatment and exercise together. ^[4]

These models mimic some features of age-related muscle loss (sarcopenia), but no human muscle mass, strength, or fall outcome has been measured. In the 2024 study, the groups consisted of 7–10 animals. ^[4]

Where does the evidence come from?

All four 5-amino-1MQ mouse studies summarized on this page carry the signature of the same researchers (Watowich and Neelakantan). In the 2018 and 2019 papers, the authors declared no conflict of interest. ^{[1] [3]} In the 2024 papers, the senior author was declared as the founder of a company developing NNMT inhibitors, and some of the other authors as current or former employees of the same company. ^{[4] [5]} This does not invalidate the results, but it indicates that the findings have not been replicated by independent laboratories.

What is the NAD+ and aging claim based on?

5-Amino-1MQ is often presented as an “NAD+ booster” and “anti-aging.” The source of this claim is that NNMT diverts nicotinamide away from the NAD+ pathway and that inhibitors raised NAD+ levels in fat cell culture. ^[1] There is no NAD+ change, aging marker, or lifespan outcome measured in humans with 5-amino-1MQ. The human evidence for NAD+ precursors is covered in separate guides: NAD+, NMN.

The overall state of the field is also cautious. A 2026 review examining the clinical translation of NNMT inhibitors writes that, because of inadequate target engagement, low bioavailability, and unknown safety profiles, these molecules have shown limited success even at the preclinical stage, and that newer-generation compounds are trying to address these problems. Two authors of the review are listed as inventors on a patent application filed for a different NNMT inhibitor. ^[6]

Is it safe? What is known and unknown

There are no human safety data. No observable side effects were reported in mouse studies; in the 2018 study, the dose-finding phase was carried out with only two mice. ^[1] In the 2024 study, a laboratory screen across a broad panel of targets observed that 5-amino-1MQ also inhibited human MAO-A (67.4% inhibition at 10 µM); the authors wrote that part of the improvement in glucose tolerance might stem from this effect. ^[5] The significance of this off-target effect in humans and drug interactions have not been examined.

The unknowns are these: absorption and elimination in humans, liver, kidney, and nervous system safety with long-term use, pregnancy, and drug interactions. Whether the labeled substance is actually present in unregulated products, and its purity, are also unknown. General injection-related risks are covered in a separate guide: Peptide side effects

FDA, WADA, and Türkiye: what is the legal status?

United States

In the FDA’s May 14, 2026 nomination list for 503A (pharmacy compounding), 5-amino-1MQ is not in any of categories 1, 2, or 3. ^[9] In a warning letter dated January 20, 2026, FDA found that an outsourcing facility registered under 503B was compounding drugs with 5-amino-1MQ and NAD+. According to the letter, because these substances are not on the 503B bulk substances list and were not used to make a drug on the drug shortage list, products compounded with them cannot benefit from the 503B exemptions; the facility could not document the fate of these products or that production had stopped. ^[8] The legal and practical meaning of the “for research purposes” label is covered in a separate guide: What does research peptide mean?

Sport (WADA)

5-Amino-1MQ is not named in the WADA list valid from January 1, 2026. Section S0 of the list prohibits at all times, in and out of competition, any pharmacological substance not covered by later sections and not approved by any governmental health authority for human therapeutic use, for example drugs in preclinical or clinical development. ^[10] Published data on 5-amino-1MQ are at the preclinical level; the classification of a specific substance is within WADA’s authority.

Türkiye

The October 16, 2026 TİTCK Licensed Human Medicinal Products List contains no product with 5-amino-1MQ as active ingredient. ^[11] There is also no row naming it in the Ministry of Agriculture and Forestry Supplement Restricted Substances List (September 21, 2026). ^[14]

Article 19 of Law No. 1262 punishes with imprisonment of one to five years those who manufacture unlicensed preparations and those who knowingly sell, offer for sale, or have them sold; the same penalty is provided for those who sell or advertise a product with the claim of diagnosing or treating diseases even if it is not a preparation. Importing unlicensed preparations for commercial purposes counts as smuggling. Additional Article 7 of the Law provides that the Ministry may permit the bringing in of unlicensed preparations for examination, trial, or personal treatment, within an amount to be accepted by the Ministry; this is a permit mechanism. ^[12] Under Article 24 of Law No. 6197, medicines cannot be sold online or in any other electronic medium. ^[13]

The general legal framework for peptides and similar products: Are peptides legal?

Evidence table: claim, population, and limits

One final point completes this table: as of October 19, 2026, no registered study appears on ClinicalTrials.gov with either a “5-amino-1MQ” or a “5-amino-1-methylquinolinium” search. ^[7] Efficacy and safety in humans remain a question not yet asked.

Limits of this guide

This page summarizes published animal studies on 5-amino-1MQ and documents from official institutions. It gives no dose, cycle, preparation, administration technique, or product-sourcing information; procedures in animal studies cannot be transferred to humans. Drugs with evidence for weight management are covered in separate guides: GLP-1 agonists